Eyepoint Pharmaceuticals (EYPT) to Release Earnings on Wednesday

Eyepoint Pharmaceuticals (NASDAQ:EYPT) is projected to issue its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect the company to announce earnings of ($0.78) per share and revenue of $1.0060 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 2, 2026 at 12:30 PM ET.

Eyepoint Pharmaceuticals Trading Down 0.1%

Shares of Eyepoint Pharmaceuticals stock opened at $17.05 on Wednesday. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of -5.70 and a beta of 1.76. Eyepoint Pharmaceuticals has a twelve month low of $3.91 and a twelve month high of $19.11. The business’s 50 day simple moving average is $15.73 and its 200-day simple moving average is $14.03.

Wall Street Analysts Forecast Growth

EYPT has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Thursday, January 22nd. Cantor Fitzgerald upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, November 25th. TD Cowen upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Friday, December 19th. Finally, Royal Bank Of Canada upped their price objective on Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $29.25.

Insiders Place Their Bets

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 42,544 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $17.10, for a total value of $727,502.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.46% of the company’s stock.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. lifted its holdings in shares of Eyepoint Pharmaceuticals by 16.6% during the 4th quarter. Invesco Ltd. now owns 339,004 shares of the company’s stock valued at $6,194,000 after buying an additional 48,186 shares during the last quarter. Virtus Investment Advisers LLC increased its stake in shares of Eyepoint Pharmaceuticals by 29.5% during the 4th quarter. Virtus Investment Advisers LLC now owns 16,638 shares of the company’s stock worth $304,000 after purchasing an additional 3,795 shares during the last quarter. Susquehanna Portfolio Strategies LLC raised its holdings in shares of Eyepoint Pharmaceuticals by 22.5% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 74,944 shares of the company’s stock valued at $1,369,000 after purchasing an additional 13,750 shares in the last quarter. Suvretta Capital Management LLC raised its holdings in shares of Eyepoint Pharmaceuticals by 26.4% during the 4th quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company’s stock valued at $143,012,000 after purchasing an additional 1,634,970 shares in the last quarter. Finally, Orbimed Advisors LLC lifted its stake in shares of Eyepoint Pharmaceuticals by 37.4% in the 4th quarter. Orbimed Advisors LLC now owns 2,468,314 shares of the company’s stock valued at $45,096,000 after purchasing an additional 672,314 shares during the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.